Developer docs
API playgroundTry for free, no card

Search company profiles

Xencor

Full company profile

uuid0002h8e

Namestring
Xencor
Legal namestring
Xencor, Inc.
Websiteurl
xencor.com
Company typeenum
Public
Founded yearint
1997
Descriptiontext

Xencor, Inc. is a clinical-stage biopharmaceutical company founded in 1997 and headquartered in Pasadena, California, that engineers monoclonal antibody therapeutics for cancer, autoimmune disorders, and inflammatory diseases. The company's core asset is the proprietary XmAb protein engineering platform, which makes precise amino-acid-level alterations to the Fc domain of antibodies to enhance effector function, half-life, immune inhibition, or bispecific architecture. The platform comprises four plug-and-play modules — Bispecific Fc, Cytotoxic Fc (40-fold higher FcγRIIIa affinity), Immune Inhibitor Fc (400-fold higher FcγRIIb affinity), and Xtend Fc (up to 3-fold extended half-life) — plus a 2+1 bispecific antibody format that biases activity toward tumor cells with higher antigen density. Xencor protects this platform with more than 1,500 patents worldwide.

The company operates a dual business model. First, it advances a wholly-owned clinical pipeline including XmAb942 (Phase 2b for ulcerative colitis), XmAb819 (Phase 1 for renal cell carcinoma), XmAb541 (Phase 1 for ovarian cancer), XmAb808 (Phase 1 B7-H3 x CD28), XmAb657 (Phase 1 for autoimmune disease), Plamotamab (Phase 1b for rheumatoid arthritis), and preclinical XmAb412. Second, it licenses XmAb Fc domain technology to major pharmaceutical partners — Alexion (Ultomiris), Incyte (Monjuvi/Minjuvi), Amgen (xaluritamig), Novartis, Vir Biotechnology, Zenas, Astellas, and Johnson & Johnson — earning upfront payments, milestones, and royalties. Three partner-marketed XmAb medicines are currently approved and generating royalties, and more than 20 XmAb-engineered programs are in clinical testing. Revenue is milestone- and royalty-driven, reaching $125.6 million in FY2025 with a net loss of $91.9 million, supported by a $610.8 million cash position expected to fund operations into mid-2028.

Short descriptiontext

Xencor is a clinical-stage biopharmaceutical company that engineers monoclonal antibody therapeutics using its proprietary XmAb Fc domain platform for cancer and autoimmune diseases, operating a dual model of wholly-owned clinical programs and licensed partnerships with major pharmaceutical companies that have produced three marketed drugs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersPasadena, United States
HQ citystring
Pasadena
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
engineered antibody therapeutics, bispecific antibody platform, Fc domain engineering, oncology drug development, biopharmaceutical licensing
Industry3 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing Royalties
TypeLicensing Royalties
Description

Xencor generates revenue through licensing its XmAb Fc domain technology to pharmaceutical partners. The company earns royalties on net sales of approved drugs that use its technology, such as Ultomiris (Alexion) and Monjuvi/Minjuvi (Incyte).

ad-hoc-news.de
2Partnership and License Agreement Revenue
TypeLicensing Royalties
Description

Revenue from Alexion and Incyte license agreements, including upfront payments, milestone payments, and ongoing royalties. Full-year 2025 revenue was $125.6 million driven primarily by these agreements.

businesswire.com
3Public Stock Offering
TypeOthers
Description

Xencor raised approximately $201.3 million through a public stock offering of over 8 million shares of common stock and pre-funded warrants for general corporate purposes including R&D.

investors.xencor.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Xencor develops engineered monoclonal antibody therapeutics using its proprietary XmAb protein engineering platform, which creates precise alterations to antibody Fc domains to enhance natural functions such as potency, half-life, and immune engagement. The company operates a dual model: (1) wholly-owned clinical-stage drug candidates in oncology and autoimmune diseases, and (2) licensing XmAb Fc domain technology to major pharmaceutical partners who develop and commercialize products incorporating the technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 40-fold greater affinity for FcγRIIIa with cytotoxic Fc domains
+4 more records
Product overview1 text field

Xencor is a clinical-stage biopharmaceutical company developing a diversified portfolio of engineered antibody therapeutics using its proprietary XmAb protein engineering platform. The company operates two core business models: (1) wholly-owned clinical programs including XmAb819 (Phase 1, renal cell carcinoma), XmAb541 (Phase 1, ovarian cancer), XmAb808 (Phase 1, B7-H3 x CD28 tumor co-stimulation), XmAb942 (Phase 2b, ulcerative colitis), Plamotamab (Phase 1b, rheumatoid arthritis), XmAb657 (Phase 1, idiopathic inflammatory myopathy), and preclinical XmAb412 (TL1A x IL23 bispecific); and (2) partnered/licensed programs including Ultomiris (approved, Alexion), Monjuvi/Minjuvi (approved, Incyte), Xaluritamig (Phase 3, Amgen), obexelimab, tobevibart, ASP2138, and JNJ programs. The XmAb platform comprises four plug-and-play Fc domain technologies: Bispecific Fc Domain (enabling dual-targeting), Cytotoxic Fc Domain (enhancing NK cell activity), Immune Inhibitor Fc Domain (for autoimmune applications), and Xtend Fc Domain (extending half-life). More than 20 programs are in clinical testing with three XmAb medicines marketed by partners.

Product and service19 records
1XmAb Bispecific Fc Domain
CategoryTechnology Platform
Description

A plug-and-play Fc domain technology enabling creation of stable, bispecific antibodies with full-length antibody properties that can be produced with standard manufacturing methods. Licensed to pharmaceutical partners for engineering dual-targeting antibodies.

2XmAb Cytotoxic Fc Domain
CategoryTechnology Platform
Description

An Fc domain technology providing 40-fold greater affinity for FcγRIIIa via two amino acid changes, enhancing Natural Killer cell and macrophage activation for improved tumor cell elimination. Used in partnered programs and the approved therapy tafasitamab.

3XmAb Immune Inhibitor Fc Domain
CategoryTechnology Platform
Description

An Fc domain variant providing 400-fold increased binding affinity for FcγRIIb (CD32b) for potent immune inhibition and rapid antigen clearance. Applied to antibodies targeting B-cell surface markers for autoimmune disease treatment.

4Xtend Fc Domain
CategoryTechnology Platform
Description

An Fc domain technology providing up to 3-fold increased circulating half-life through enhanced binding to the FcRn receptor. Applied in 13 clinical-stage programs and the approved therapy Ultomiris, enabling reduced dosing frequency and improved patient convenience.

5XmAb819 (ENPP3 x CD3)
CategoryClinical Program
Description

A tumor-targeted, T-cell engaging XmAb 2+1 bispecific antibody in development for patients with advanced clear cell renal cell carcinoma. Engages ENPP3 (highly expressed on kidney cancers) and CD3 (T-cell receptor component) for targeted tumor cell killing.

6XmAb541 (CLDN6 x CD3)
CategoryClinical Program
Description

A tumor-targeted, T-cell engaging XmAb 2+1 bispecific antibody in development for patients with ovarian cancer and other solid tumors. Targets claudin-6 (CLDN6), a tumor-associated antigen, and CD3 for potent T-cell mediated tumor killing.

7XmAb808 (B7-H3 x CD28)
CategoryClinical Program
Description

A tumor-selective, co-stimulatory XmAb 2+1 bispecific antibody designed to bind to the broadly expressed tumor antigen B7-H3 and selectively to CD28 for tumor-conditional T-cell co-stimulation (Signal 2), used in combination with checkpoint inhibitors or CD3 T-cell engagers.

8XmAb942 (Xtend TL1A)
CategoryClinical Program
Description

A monospecific anti-TL1A antibody utilizing Xtend Fc Domain and proprietary Fc silencing technology, with potentially class-leading potency for inflammatory bowel diseases including ulcerative colitis and Crohn's disease.

9Plamotamab (CD20 x CD3)
CategoryClinical Program
Description

A B-cell depleting bispecific T-cell engager in development for rheumatoid arthritis and previously studied in hematologic cancers. Targets CD20 on B cells and CD3 on T cells for immune-mediated B-cell depletion.

10XmAb657 (CD19 x CD3)
CategoryClinical Program
Description

A rationally designed CD19 x CD3 bispecific T-cell engager for patients with autoimmune diseases, including idiopathic inflammatory myopathy. Utilizes XmAb 2+1 bispecific antibody format and Xtend Fc technology for potent, potentially long-acting B-cell depletion.

11Ultomiris (ravulizumab-cwvz)
CategoryPartnered/Licensed Program
Description

An approved therapy developed and marketed by Alexion Pharmaceuticals using Xencor's Xtend Fc domain technology to extend half-life. Marketed for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).

12Monjuvi/Minjuvi (tafasitamab-cxix)
CategoryPartnered/Licensed Program
Description

A CD19-directed cytolytic antibody using Xencor's Cytotoxic Fc Domain technology. Approved in the U.S. and EU in combination with lenalidomide for relapsed or refractory DLBCL and follicular lymphoma. Marketed by Incyte (acquired global rights from MorphoSys in February 2024).

13Xaluritamig (STEAP1 x CD3)
CategoryPartnered/Licensed Program
Description

A STEAP1 x CD3 XmAb 2+1 bispecific antibody licensed to Amgen for metastatic castration-resistant prostate cancer. Currently in Phase 3 clinical study.

14Obexelimab (CD19)
CategoryPartnered/Licensed Program
Description

An anti-CD19 antibody using Xencor's Immune Inhibitor Fc Domain technology, licensed exclusively worldwide to Zenas BioPharma for development and commercialization in autoimmune diseases including IgG4-related disease.

15Tobevibart
CategoryPartnered/Licensed Program
Description

An investigational antibody incorporating Xtend and other XmAb Fc technologies, developed by Vir Biotechnology for hepatitis Delta, currently in clinical trials.

16ASP2138 (Claudin 18.2 x CD3)
CategoryPartnered/Licensed Program
Description

A Claudin 18.2 x CD3 bispecific antibody licensed to Astellas for gastric, gastroesophageal junction adenocarcinoma, and pancreatic adenocarcinoma.

17JNJ-9401 (PSMA x CD28)
CategoryPartnered/Licensed Program
Description

A PSMA x CD28 bispecific antibody in development by Johnson & Johnson Innovative Medicine using Xencor's bispecific Fc domain technology.

18JNJ-1493 (CD20 x CD28)
CategoryPartnered/Licensed Program
Description

A CD20 x CD28 bispecific antibody in development by Johnson & Johnson Innovative Medicine for B-cell tumors using Xencor's bispecific technology.

19XmAb412 (TL1A x IL23p19)
CategoryPreclinical Program
Description

A bispecific antibody combining anti-TL1A and anti-IL23(p19) specificities designed for inflammatory bowel disease treatment, utilizing Xencor's bispecific Fc domain technology.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Alexion uses Xencor's Xtend Fc domain technology to enhance half-life of Ultomiris (ravulizumab-cwvz), approved for PNH, aHUS, gMG, and NMOSD. This partnership is subject to a royalty dispute regarding U.S. sales payments.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Incyte markets Monjuvi (tafasitamab-cxix) in the U.S. and Minjuvi in Europe/Canada - a CD19-directed cytolytic antibody using Xencor's cytotoxic Fc domain. Approved for r/r DLBCL and r/r FL. Xencor originally discovered tafasitamab and licensed to MorphoSys in 2010; Incyte acquired global rights in February 2024.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Amgen licenses XmAb bispecific Fc domain to create xaluritamig (STEAP1 x CD3), a 2+1 bispecific antibody in Phase 3 for metastatic castration-resistant prostate cancer.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Strategic collaboration for bispecific programs including XmAb 14045 and XmAb 13676. Represents a significant partnership for advancing novel bispecific antibody candidates.

Strategic tierNotableTypeOEM/ Whitelabel/ Licensing Partner
Description

Vir Biotechnology uses Xtend and other XmAb Fc technologies for tobevibart, an investigational antibody targeting hepatitis delta. Also incorporated Xtend Fc into sotrovimab for SARS-CoV-2.

Strategic tierNotableTypeOEM/ Whitelabel/ Licensing Partner
Description

Exclusive worldwide license to develop and commercialize obexelimab (XmAb5871), an anti-CD19 antibody using immune inhibitor Fc domain for autoimmune diseases including IgG4-related disease.

Strategic tierNotableTypeOEM/ Whitelabel/ Licensing Partner
Description

Licenses bispecific Fc domain for ASP2138 (Claudin 18.2 x CD3) in development for gastric, gastroesophageal junction adenocarcinoma, and pancreatic adenocarcinoma.

Strategic tierNotableTypeOEM/ Whitelabel/ Licensing Partner
Description

Licenses bispecific programs JNJ-9401 (PSMA x CD28) and JNJ-1493 (CD20 x CD28) for B-cell tumors and prostate cancer.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharma developing bispecific antibodies and antibody-based therapeutics for cancer using proprietary DART and TRIDENT platforms. Direct competitor in bispecific antibody space with similar partnership-heavy business model.

TypeDirect peer
Description

Clinical-stage biopharma developing multifunctional bispecific antibodies using Azymetric and EFECT platforms. Directly comparable as a platform-based antibody engineering company with both wholly-owned and partnered programs.

TypeBroad incumbent
Description

Established antibody therapeutics company with proprietary DuoBody bispecific platform and strong royalty stream from approved drugs including Darzalex. Broader incumbent in bispecific antibody development with multiple approved products.

TypeDirect peer
Description

Clinical-stage biopharma developing engineered antibody therapeutics using single-domain antibody platform. Direct competitor in protein engineering space with similar size and partnership model.

TypeEmerging player
Description

Clinical-stage oncology company developing probody therapeutics - masked antibodies that are activated in tumor microenvironment. Comparable as an antibody engineering platform company with partnered programs.

TypeEmerging player
Description

Clinical-stage biopharma developing bispecific antibodies for oncology with multiple clinical-stage programs. Directly comparable as a smaller clinical-stage bispecific antibody company with novel engineering approaches.

TypeBroad incumbent
Description

Large biopharma with proprietary VelocImmune antibody platform and approved bispecific antibodies (linvoseltamab, odronextamab). Broader incumbent with overlapping antibody engineering capabilities and significantly more resources.

TypeEmerging player
Description

Clinical-stage company developing T-cell engagers using proprietary TriTAC platform. Directly comparable as a bispecific T-cell engager developer; acquired by Merck in 2024 validating platform value.

TypeEmerging player
Description

Clinical-stage company developing COBRA T-cell engagers with conditional activation. Comparable as a bispecific antibody developer focused on T-cell engagement, though smaller and earlier stage than Xencor.

TypeOthers
Description

Antibody-drug conjugate (ADC) developer acquired by AbbVie in 2024. Adjacent in the antibody therapeutics space with overlapping target indications in oncology, but different modality (ADCs vs engineered Fc domains).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Xencor

Biopharmaceuticalsxencor.com

Xencor is a clinical-stage biopharmaceutical company that engineers monoclonal antibody therapeutics using its proprietary XmAb Fc domain platform for cancer and autoimmune diseases, operating a dual model of wholly-owned clinical programs and licensed partnerships with major pharmaceutical companies that have produced three marketed drugs.

What Xencor does

Xencor, Inc. is a clinical-stage biopharmaceutical company founded in 1997 and headquartered in Pasadena, California, that engineers monoclonal antibody therapeutics for cancer, autoimmune disorders, and inflammatory diseases. The company's core asset is the proprietary XmAb protein engineering platform, which makes precise amino-acid-level alterations to the Fc domain of antibodies to enhance effector function, half-life, immune inhibition, or bispecific architecture. The platform comprises four plug-and-play modules — Bispecific Fc, Cytotoxic Fc (40-fold higher FcγRIIIa affinity), Immune Inhibitor Fc (400-fold higher FcγRIIb affinity), and Xtend Fc (up to 3-fold extended half-life) — plus a 2+1 bispecific antibody format that biases activity toward tumor cells with higher antigen density. Xencor protects this platform with more than 1,500 patents worldwide.

The company operates a dual business model. First, it advances a wholly-owned clinical pipeline including XmAb942 (Phase 2b for ulcerative colitis), XmAb819 (Phase 1 for renal cell carcinoma), XmAb541 (Phase 1 for ovarian cancer), XmAb808 (Phase 1 B7-H3 x CD28), XmAb657 (Phase 1 for autoimmune disease), Plamotamab (Phase 1b for rheumatoid arthritis), and preclinical XmAb412. Second, it licenses XmAb Fc domain technology to major pharmaceutical partners — Alexion (Ultomiris), Incyte (Monjuvi/Minjuvi), Amgen (xaluritamig), Novartis, Vir Biotechnology, Zenas, Astellas, and Johnson & Johnson — earning upfront payments, milestones, and royalties. Three partner-marketed XmAb medicines are currently approved and generating royalties, and more than 20 XmAb-engineered programs are in clinical testing. Revenue is milestone- and royalty-driven, reaching $125.6 million in FY2025 with a net loss of $91.9 million, supported by a $610.8 million cash position expected to fund operations into mid-2028.

Xencor firmographics

Firmographics
Name
Xencor
Legal name
Xencor, Inc.
Website
https://xencor.com
Company type
Public
Founded year
1997
Operating status
Operating
Headcount range
251–500 employees
Short description
Xencor is a clinical-stage biopharmaceutical company that engineers monoclonal antibody therapeutics using its proprietary XmAb Fc domain platform for cancer and autoimmune diseases, operating a dual model of wholly-owned clinical programs and licensed partnerships with major pharmaceutical companies that have produced three marketed drugs.
Ownership category
akta.pro rank

Xencor industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Engineered antibody therapeutics
  • Bispecific antibody platform
  • Fc domain engineering
  • Oncology drug development
  • Biopharmaceutical licensing

Where Xencor is headquartered

Location

Headquarters

HQ city
Pasadena
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Xencor business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Licensing Royalties: Xencor generates revenue through licensing its XmAb Fc domain technology to pharmaceutical partners. The company earns royalties on net sales of approved drugs that use its technology, such as Ultomiris (Alexion) and Monjuvi/Minjuvi (Incyte).
  2. Partnership and License Agreement Revenue: Revenue from Alexion and Incyte license agreements, including upfront payments, milestone payments, and ongoing royalties. Full-year 2025 revenue was $125.6 million driven primarily by these agreements.
  3. Public Stock Offering: Xencor raised approximately $201.3 million through a public stock offering of over 8 million shares of common stock and pre-funded warrants for general corporate purposes including R&D.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Xencor product offering

Product offering

Core offering

Xencor develops engineered monoclonal antibody therapeutics using its proprietary XmAb protein engineering platform, which creates precise alterations to antibody Fc domains to enhance natural functions such as potency, half-life, and immune engagement. The company operates a dual model: (1) wholly-owned clinical-stage drug candidates in oncology and autoimmune diseases, and (2) licensing XmAb Fc domain technology to major pharmaceutical partners who develop and commercialize products incorporating the technology.

Product overview

Xencor is a clinical-stage biopharmaceutical company developing a diversified portfolio of engineered antibody therapeutics using its proprietary XmAb protein engineering platform. The company operates two core business models: (1) wholly-owned clinical programs including XmAb819 (Phase 1, renal cell carcinoma), XmAb541 (Phase 1, ovarian cancer), XmAb808 (Phase 1, B7-H3 x CD28 tumor co-stimulation), XmAb942 (Phase 2b, ulcerative colitis), Plamotamab (Phase 1b, rheumatoid arthritis), XmAb657 (Phase 1, idiopathic inflammatory myopathy), and preclinical XmAb412 (TL1A x IL23 bispecific); and (2) partnered/licensed programs including Ultomiris (approved, Alexion), Monjuvi/Minjuvi (approved, Incyte), Xaluritamig (Phase 3, Amgen), obexelimab, tobevibart, ASP2138, and JNJ programs. The XmAb platform comprises four plug-and-play Fc domain technologies: Bispecific Fc Domain (enabling dual-targeting), Cytotoxic Fc Domain (enhancing NK cell activity), Immune Inhibitor Fc Domain (for autoimmune applications), and Xtend Fc Domain (extending half-life). More than 20 programs are in clinical testing with three XmAb medicines marketed by partners.

Differentiator

Problem solved

Functional benefit

Products and services

  • XmAb Bispecific Fc Domain A plug-and-play Fc domain technology enabling creation of stable, bispecific antibodies with full-length antibody properties that can be produced with standard manufacturing methods. Licensed to pharmaceutical partners for engineering dual-targeting antibodies.
  • XmAb Cytotoxic Fc Domain An Fc domain technology providing 40-fold greater affinity for FcγRIIIa via two amino acid changes, enhancing Natural Killer cell and macrophage activation for improved tumor cell elimination. Used in partnered programs and the approved therapy tafasitamab.
  • XmAb Immune Inhibitor Fc Domain An Fc domain variant providing 400-fold increased binding affinity for FcγRIIb (CD32b) for potent immune inhibition and rapid antigen clearance. Applied to antibodies targeting B-cell surface markers for autoimmune disease treatment.
  • Xtend Fc Domain An Fc domain technology providing up to 3-fold increased circulating half-life through enhanced binding to the FcRn receptor. Applied in 13 clinical-stage programs and the approved therapy Ultomiris, enabling reduced dosing frequency and improved patient convenience.
  • XmAb819 (ENPP3 x CD3) A tumor-targeted, T-cell engaging XmAb 2+1 bispecific antibody in development for patients with advanced clear cell renal cell carcinoma. Engages ENPP3 (highly expressed on kidney cancers) and CD3 (T-cell receptor component) for targeted tumor cell killing.
  • XmAb541 (CLDN6 x CD3) A tumor-targeted, T-cell engaging XmAb 2+1 bispecific antibody in development for patients with ovarian cancer and other solid tumors. Targets claudin-6 (CLDN6), a tumor-associated antigen, and CD3 for potent T-cell mediated tumor killing.
  • XmAb808 (B7-H3 x CD28) A tumor-selective, co-stimulatory XmAb 2+1 bispecific antibody designed to bind to the broadly expressed tumor antigen B7-H3 and selectively to CD28 for tumor-conditional T-cell co-stimulation (Signal 2), used in combination with checkpoint inhibitors or CD3 T-cell engagers.
  • XmAb942 (Xtend TL1A) A monospecific anti-TL1A antibody utilizing Xtend Fc Domain and proprietary Fc silencing technology, with potentially class-leading potency for inflammatory bowel diseases including ulcerative colitis and Crohn's disease.
  • Plamotamab (CD20 x CD3) A B-cell depleting bispecific T-cell engager in development for rheumatoid arthritis and previously studied in hematologic cancers. Targets CD20 on B cells and CD3 on T cells for immune-mediated B-cell depletion.
  • XmAb657 (CD19 x CD3) A rationally designed CD19 x CD3 bispecific T-cell engager for patients with autoimmune diseases, including idiopathic inflammatory myopathy. Utilizes XmAb 2+1 bispecific antibody format and Xtend Fc technology for potent, potentially long-acting B-cell depletion.
  • Ultomiris (ravulizumab-cwvz) An approved therapy developed and marketed by Alexion Pharmaceuticals using Xencor's Xtend Fc domain technology to extend half-life. Marketed for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).
  • Monjuvi/Minjuvi (tafasitamab-cxix) A CD19-directed cytolytic antibody using Xencor's Cytotoxic Fc Domain technology. Approved in the U.S. and EU in combination with lenalidomide for relapsed or refractory DLBCL and follicular lymphoma. Marketed by Incyte (acquired global rights from MorphoSys in February 2024).
  • Xaluritamig (STEAP1 x CD3) A STEAP1 x CD3 XmAb 2+1 bispecific antibody licensed to Amgen for metastatic castration-resistant prostate cancer. Currently in Phase 3 clinical study.
  • Obexelimab (CD19) An anti-CD19 antibody using Xencor's Immune Inhibitor Fc Domain technology, licensed exclusively worldwide to Zenas BioPharma for development and commercialization in autoimmune diseases including IgG4-related disease.
  • Tobevibart An investigational antibody incorporating Xtend and other XmAb Fc technologies, developed by Vir Biotechnology for hepatitis Delta, currently in clinical trials.
  • ASP2138 (Claudin 18.2 x CD3) A Claudin 18.2 x CD3 bispecific antibody licensed to Astellas for gastric, gastroesophageal junction adenocarcinoma, and pancreatic adenocarcinoma.
  • JNJ-9401 (PSMA x CD28) A PSMA x CD28 bispecific antibody in development by Johnson & Johnson Innovative Medicine using Xencor's bispecific Fc domain technology.
  • JNJ-1493 (CD20 x CD28) A CD20 x CD28 bispecific antibody in development by Johnson & Johnson Innovative Medicine for B-cell tumors using Xencor's bispecific technology.
  • XmAb412 (TL1A x IL23p19) A bispecific antibody combining anti-TL1A and anti-IL23(p19) specificities designed for inflammatory bowel disease treatment, utilizing Xencor's bispecific Fc domain technology.

Quantifiable outcome

  • 40-fold greater affinity for FcγRIIIa with cytotoxic Fc domains
  • +4 more outcomes

Companies that use Xencor

Customer profile

Named customers8 records

Segments2 records

Ideal customer profiles1 record

Xencor technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Xencor partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, major and notable.

  • Alexion PharmaceuticalscoreOEM/ Whitelabel/ Licensing PartnerAlexion uses Xencor's Xtend Fc domain technology to enhance half-life of Ultomiris (ravulizumab-cwvz), approved for PNH, aHUS, gMG, and NMOSD. This partnership is subject to a royalty dispute regarding U.S. sales payments.
  • IncytecoreOEM/ Whitelabel/ Licensing PartnerIncyte markets Monjuvi (tafasitamab-cxix) in the U.S. and Minjuvi in Europe/Canada - a CD19-directed cytolytic antibody using Xencor's cytotoxic Fc domain. Approved for r/r DLBCL and r/r FL. Xencor originally discovered tafasitamab and licensed to MorphoSys in 2010; Incyte acquired global rights in February 2024.
  • AmgencoreOEM/ Whitelabel/ Licensing PartnerAmgen licenses XmAb bispecific Fc domain to create xaluritamig (STEAP1 x CD3), a 2+1 bispecific antibody in Phase 3 for metastatic castration-resistant prostate cancer.
  • NovartismajorStrategic or Co-development PartnerStrategic collaboration for bispecific programs including XmAb 14045 and XmAb 13676. Represents a significant partnership for advancing novel bispecific antibody candidates.
  • Vir BiotechnologynotableOEM/ Whitelabel/ Licensing PartnerVir Biotechnology uses Xtend and other XmAb Fc technologies for tobevibart, an investigational antibody targeting hepatitis delta. Also incorporated Xtend Fc into sotrovimab for SARS-CoV-2.
  • Zenas BioPharmanotableOEM/ Whitelabel/ Licensing PartnerExclusive worldwide license to develop and commercialize obexelimab (XmAb5871), an anti-CD19 antibody using immune inhibitor Fc domain for autoimmune diseases including IgG4-related disease.
  • Astellas PharmanotableOEM/ Whitelabel/ Licensing PartnerLicenses bispecific Fc domain for ASP2138 (Claudin 18.2 x CD3) in development for gastric, gastroesophageal junction adenocarcinoma, and pancreatic adenocarcinoma.
  • Johnson & Johnson Innovative MedicinenotableOEM/ Whitelabel/ Licensing PartnerLicenses bispecific programs JNJ-9401 (PSMA x CD28) and JNJ-1493 (CD20 x CD28) for B-cell tumors and prostate cancer.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Xencor competitors and assessment

Company assessment

Direct peers

  • MacroGenics: Clinical-stage biopharma developing bispecific antibodies and antibody-based therapeutics for cancer using proprietary DART and TRIDENT platforms. Direct competitor in bispecific antibody space with similar partnership-heavy business model.
  • Zymeworks: Clinical-stage biopharma developing multifunctional bispecific antibodies using Azymetric and EFECT platforms. Directly comparable as a platform-based antibody engineering company with both wholly-owned and partnered programs.
  • Inhibrx Biosciences: Clinical-stage biopharma developing engineered antibody therapeutics using single-domain antibody platform. Direct competitor in protein engineering space with similar size and partnership model.

Broad incumbents

  • Genmab: Established antibody therapeutics company with proprietary DuoBody bispecific platform and strong royalty stream from approved drugs including Darzalex. Broader incumbent in bispecific antibody development with multiple approved products.
  • Regeneron Pharmaceuticals: Large biopharma with proprietary VelocImmune antibody platform and approved bispecific antibodies (linvoseltamab, odronextamab). Broader incumbent with overlapping antibody engineering capabilities and significantly more resources.

Emerging players

  • CytomX Therapeutics: Clinical-stage oncology company developing probody therapeutics - masked antibodies that are activated in tumor microenvironment. Comparable as an antibody engineering platform company with partnered programs.
  • Compass Therapeutics: Clinical-stage biopharma developing bispecific antibodies for oncology with multiple clinical-stage programs. Directly comparable as a smaller clinical-stage bispecific antibody company with novel engineering approaches.
  • Harpoon Therapeutics: Clinical-stage company developing T-cell engagers using proprietary TriTAC platform. Directly comparable as a bispecific T-cell engager developer; acquired by Merck in 2024 validating platform value.
  • Maverick Therapeutics: Clinical-stage company developing COBRA T-cell engagers with conditional activation. Comparable as a bispecific antibody developer focused on T-cell engagement, though smaller and earlier stage than Xencor.

Others

  • ImmunoGen: Antibody-drug conjugate (ADC) developer acquired by AbbVie in 2024. Adjacent in the antibody therapeutics space with overlapping target indications in oncology, but different modality (ADCs vs engineered Fc domains).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Xencor financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Xencor leadership team

Management profile

Number of profiles

Profiles10 records

Xencor funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Xencor M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xencor

What does Xencor do?

Xencor develops engineered monoclonal antibody therapeutics using its proprietary XmAb protein engineering platform, which creates precise alterations to antibody Fc domains to enhance natural functions such as potency, half-life, and immune engagement. The company operates a dual model: (1) wholly-owned clinical-stage drug candidates in oncology and autoimmune diseases, and (2) licensing XmAb Fc domain technology to major pharmaceutical partners who develop and commercialize products incorporating the technology.

Is Xencor a public or private company?

Xencor is a public company. It is classified as public and is currently operating.

When was Xencor founded?

Xencor was founded in 1997. It employs 251 to 500 people.

Where is Xencor based?

Xencor is headquartered in Pasadena, United States, in the North America region.

How does Xencor make money?

Three revenue lines are on record. Licensing Royalties are the primary driver. The others are partnership and License Agreement Revenue and public Stock Offering.

Who are Xencor's main competitors?

Direct peers on record are MacroGenics, Zymeworks and Inhibrx Biosciences. Broad incumbents are Genmab and Regeneron Pharmaceuticals. Emerging players are CytomX Therapeutics, Compass Therapeutics, Harpoon Therapeutics and Maverick Therapeutics. ImmunoGen is listed as an others.

Does Xencor have an API?

No public API is recorded for Xencor.

What industry is Xencor in?

Xencor's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ChartmillXencor (NASDAQ:XNCR): Strong Trend, Weak SetupXencor's stock is rated a 10 on technicals with a 99.18 relative strength score, but a 3 on setup due to volatility and no clean entry. The company shows strong EPS and revenue growth, but is not yet consistently profitable, so investors are advised to wait for consolidation.Simply Wall StXencor (XNCR) Is Drawing Fresh Attention, But What Is The Market Weighing?Xencor released early Phase 1b data on subcutaneous plamotamab for rheumatoid arthritis and updated on XmAb657, driving a 167.90% year-to-date share price gain. Analysts see a 6% undervaluation with a fair value of $42.50, but a 15x P/S ratio signals valuation risk if trial execution falters.InvestorsBiotech Stocks: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?Biotech stocks showed a mixed third-quarter performance on Thursday, with Arcutis Biotherapeutics and BeOne Medicines rising while Xencor and Revolution Medicines fell. The Medical-Development Biotech group started up 2%, profitable biotechs rose over 2%, and revenue-generating stocks advanced nearly 6%.American Banking and Market NewsXencor (XNCR) Expected to Post Earnings on WednesdayXencor is expected to report Q3 2026 earnings after market close on Wednesday, November 4th, with analysts projecting a loss of $0.3341 per share and revenue of $63.00 million. The company's stock opened at $29.66, and analysts have a consensus rating of Moderate Buy with an average target price of $39.33.Defense WorldXencor (XNCR) Set to Release Quarterly Earnings on WednesdayXencor is set to release Q3 2026 earnings after market close on November 4th, with analysts expecting a loss of $0.3341 per share and revenue of $63.00 million. The company's stock has a consensus rating of Moderate Buy with an average price target of $39.33.BioPharma DiveThis week in charts: ESMO’s winners and losersModerna and Merck's cancer vaccine data at ESMO caused Moderna's shares to drop double digits despite positive results. Tango Therapeutics fell about 20% after announcing a 14% workforce cut, while Xencor rose on early kidney cancer drug data.MarketBeatXencor, Inc. $XNCR Shares Newly Bought by VestGen Advisors LLCVestGen Advisors LLC acquired a new stake in Xencor, purchasing 102,083 shares valued at approximately $2.5 million in Q3. Analysts have an average "Moderate Buy" rating with a consensus target price of $39.33, and the stock opened at $29.21.Simply Wall StDoes Phase 3 Dose Selection Change The Bull Case For Xencor (XNCR)?Xencor selected a 400 mcg/kg intravenous dose for XmAb819 in advanced clear cell renal cell carcinoma, following a 45.5% confirmed objective response rate. The company projects US$160 million revenue and US$25.5 million earnings by 2029, with a global randomized trial planned. Accelerated approval discussions with the FDA are anticipated in 2027.TradingViewRBC Capital maintains Outperform rating on Xencor, $43 price targetRBC Capital maintained an Outperform rating on Xencor with a $43 price target, implying 47.4% upside from the Oct 26 close. The target is based on strong clinical data from XmAb819, showing a 45.5% competitive clinical overall response rate, and the company's robust pipeline.MarketBeatXencor (NASDAQ:XNCR) Stock Price Target Raised at WedbushWedbush raised its Xencor target price to $45 from $30, citing an outperform rating. The stock opened at $29.18, and Xencor reported Q2 EPS of -$0.29, beating the -$0.80 consensus, with revenue of $51.22 million, up 17.4% year-over-year.